NCT04417062View on ClinicalTrials.gov

Olaparib With Ceralasertib in Recurrent Osteosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
OsteosarcomaOsteosarcoma Recurrent
Interventions
DRUG

Olaparib

Olaparib is taken by mouth, twice daily through out the 28 day study cycle.

DRUG

Ceralasertib

Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.

Trial Locations (4)

10065

Memorial Sloan Kettering, New York

77030

MD Anderson, Houston

94158

UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology, San Francisco

02115

Dana Farber Cancer Institite, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Osteosarcoma Institute

UNKNOWN

collaborator

AstraZeneca

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER